208 related articles for article (PubMed ID: 24196104)
1. A universal protein tag for delivery of SiRNA-aptamer chimeras.
Liu HY; Gao X
Sci Rep; 2013 Nov; 3():3129. PubMed ID: 24196104
[TBL] [Abstract][Full Text] [Related]
2. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing.
Bagalkot V; Gao X
ACS Nano; 2011 Oct; 5(10):8131-9. PubMed ID: 21936502
[TBL] [Abstract][Full Text] [Related]
3. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
McNamara JO; Andrechek ER; Wang Y; Viles KD; Rempel RE; Gilboa E; Sullenger BA; Giangrande PH
Nat Biotechnol; 2006 Aug; 24(8):1005-15. PubMed ID: 16823371
[TBL] [Abstract][Full Text] [Related]
4. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2.
Wullner U; Neef I; Eller A; Kleines M; Tur MK; Barth S
Curr Cancer Drug Targets; 2008 Nov; 8(7):554-65. PubMed ID: 18991566
[TBL] [Abstract][Full Text] [Related]
5. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
Zhou J; Li H; Zhang J; Piotr S; Rossi J
J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
[TBL] [Abstract][Full Text] [Related]
6. Highly efficient delivery of siRNA to a heart transplant model by a novel cell penetrating peptide-dsRNA binding domain.
Li H; Zheng X; Koren V; Vashist YK; Tsui TY
Int J Pharm; 2014 Jul; 469(1):206-13. PubMed ID: 24768403
[TBL] [Abstract][Full Text] [Related]
7. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
Sivakumar P; Kim S; Kang HC; Shim MS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
[TBL] [Abstract][Full Text] [Related]
8. Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.
Ni X; Zhang Y; Zennami K; Castanares M; Mukherjee A; Raval RR; Zhou H; DeWeese TL; Lupold SE
Mol Cancer Ther; 2015 Dec; 14(12):2797-804. PubMed ID: 26438155
[TBL] [Abstract][Full Text] [Related]
9. Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells.
Gilboa-Geffen A; Hamar P; Le MT; Wheeler LA; Trifonova R; Petrocca F; Wittrup A; Lieberman J
Mol Cancer Ther; 2015 Oct; 14(10):2279-91. PubMed ID: 26264278
[TBL] [Abstract][Full Text] [Related]
10. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
Dassie JP; Liu XY; Thomas GS; Whitaker RM; Thiel KW; Stockdale KR; Meyerholz DK; McCaffrey AP; McNamara JO; Giangrande PH
Nat Biotechnol; 2009 Sep; 27(9):839-49. PubMed ID: 19701187
[TBL] [Abstract][Full Text] [Related]
11. Stick-Based Methods for Aptamer-Mediated siRNA Targeted Delivery.
Catuogno S; Esposito CL; Giangrande PH
Methods Mol Biol; 2021; 2282():31-42. PubMed ID: 33928568
[TBL] [Abstract][Full Text] [Related]
12. Six-cell penetrating peptide-based fusion proteins for siRNA delivery.
Li H; Tsui T
Drug Deliv; 2015 May; 22(3):436-43. PubMed ID: 24491156
[TBL] [Abstract][Full Text] [Related]
13. Current progress on aptamer-targeted oligonucleotide therapeutics.
Dassie JP; Giangrande PH
Ther Deliv; 2013 Dec; 4(12):1527-46. PubMed ID: 24304250
[TBL] [Abstract][Full Text] [Related]
14. Utilizing RNA nanotechnology to construct negatively charged and ultrasound-responsive nanodroplets for targeted delivery of siRNA.
Guo L; Shi D; Shang M; Sun X; Meng D; Liu X; Zhou X; Li J
Drug Deliv; 2022 Dec; 29(1):316-327. PubMed ID: 35037525
[TBL] [Abstract][Full Text] [Related]
15. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1.
Zhou J; Lazar D; Li H; Xia X; Satheesan S; Charlins P; O'Mealy D; Akkina R; Saayman S; Weinberg MS; Rossi JJ; Morris KV
Theranostics; 2018; 8(6):1575-1590. PubMed ID: 29556342
[TBL] [Abstract][Full Text] [Related]
16. A designed recombinant fusion protein for targeted delivery of siRNA to the mouse brain.
Haroon MM; Dar GH; Jeyalakshmi D; Venkatraman U; Saba K; Rangaraj N; Patel AB; Gopal V
J Control Release; 2016 Apr; 228():120-131. PubMed ID: 26948382
[TBL] [Abstract][Full Text] [Related]
17. An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing αvβ3 integrin.
Hussain AF; Tur MK; Barth S
Nucleic Acid Ther; 2013 Jun; 23(3):203-12. PubMed ID: 23544955
[TBL] [Abstract][Full Text] [Related]
18. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.
Zhou J; Li H; Li S; Zaia J; Rossi JJ
Mol Ther; 2008 Aug; 16(8):1481-9. PubMed ID: 18461053
[TBL] [Abstract][Full Text] [Related]
19. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders.
Wang CW; Chung WH; Cheng YF; Ying NW; Peck K; Chen YT; Hung SI
J Allergy Clin Immunol; 2013 Sep; 132(3):713-722.e11. PubMed ID: 23791505
[TBL] [Abstract][Full Text] [Related]
20. Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras.
Subramanian N; Kanwar JR; Kanwar RK; Krishnakumar S
Nucleic Acid Ther; 2015 Dec; 25(6):317-22. PubMed ID: 26334953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
